Form 8-K/A

8-K/A — Genpact LTD

Accession: 0001104659-26-108942

Filed: 2026-09-18

Period: 2026-09-03

CIK: 0001398659

SIC: 8742 (SERVICES-MANAGEMENT CONSULTING SERVICES)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K/A — tm2625719d1_8ka.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2625719d1_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K/A — FORM 8-K/A

8-K/A (Primary)

Filename: tm2625719d1_8ka.htm · Sequence: 1

false

0001398659

2026-09-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 3, 2026

GENPACT LIMITED

(Exact name of registrant as specified in its

charter)

Bermuda

001-33626

98-0533350

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Canon’s Court, 22 Victoria Street

Hamilton HM 12, Bermuda

(Address of Principal Executive Offices) (Zip

Code)

Registrant’s telephone number, including

area code: (441) 298-3300

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common shares, par value $0.01 per share

New York Stock Exchange

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

EXPLANATORY NOTE

This Current Report on Form 8-K/A (this

“Amendment”) updates information disclosed in the Current Report on Form 8-K filed on September 8, 2026 (the “Original

Form 8-K”) by Genpact Limited (the “Company”) relating to the departure, effective September 8, 2026, of Michael

Weiner, the Company’s former Chief Financial Officer. This Amendment is being filed to disclose the material terms of Mr. Weiner’s

separation agreement and general release, the terms of which were not yet finalized as of the time of filing of the Original Form 8-K.

Except as set forth herein, no modifications have been made to the information contained in the Original Form 8-K, and the Company

has not updated any information contained therein to reflect events that have occurred since the date of the Original Form 8-K.

Item 5.02. Departure of Directors or Certain Officers; Election

of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Michael Weiner Departure

On September 7, 2026, the

Company and Mr. Weiner, its Chief Financial Officer, agreed that Mr. Weiner would step down as Chief Financial Officer, effective September

8, 2026, and remain employed by the Company in a transitional capacity through March 31, 2027 (the “Separation Date”). The

Company expressed its appreciation for Mr. Weiner’s contributions and service to the Company.

In connection with Mr. Weiner’s departure,

Mr. Weiner and the Company entered into a separation agreement and general release (the “Separation Agreement”), dated September

15, 2026, confirming the terms of Mr. Weiner’s separation from the Company. Pursuant to the Separation Agreement, the Company will

continue to pay Mr. Weiner his base salary, less applicable deductions and withholdings, and Mr. Weiner will continue to accrue the same

employee benefits he was eligible to receive prior to stepping down as Chief Financial Officer through the Separation Date. Mr. Weiner

will be eligible to receive the following payments and benefits on or after the Separation Date: (i) a severance payment of $683,500,

less applicable deductions, equal to twelve (12) months of Mr. Weiner’s base salary, to be paid in equal installments over the 12-month

period following the Separation Date, (ii) a lump sum cash payment of $45,327, less applicable deductions, equaling the cost that would

be payable by the Company to obtain continued heath care coverage for Mr. Weiner and his spouse and eligible dependents, as applicable,

under the Company’s employee group health plan for the 18-month period following the Separation Date, and (iii) a lump sum cash

payment of $168,534, less applicable deductions, equaling Mr. Weiner’s target annual bonus for calendar year 2027, prorated based

on the number of days he is employed in such year prior to the Separation Date.

In addition, with respect to certain of Mr. Weiner’s

outstanding unvested restricted share unit awards and performance share awards, the Separation Agreement provides for vesting of such

equity awards with respect to the number of shares that would have vested had Mr. Weiner continued in employment or service for a period

of 12 months following the Separation Date, with the number of shares, if any, vesting in respect of such performance share awards determined

based on the level of attainment of the performance objectives upon the completion of the relevant performance period during such 12-month

period and in accordance with the applicable performance share award agreement, and the number of shares in respect of such restricted

share unit awards vesting on an accelerated basis as of the Separation Date. Option awards previously vested and held by Mr. Weiner will

remain exercisable for a period of six months following the Separation Date (or, if earlier, until the expiration of the term of such

option).

Payment of the foregoing

severance payments and benefits pursuant to the Separation Agreement is conditioned on Mr. Weiner executing a general release of all claims

against the Company and its affiliates, and re-execution of a substantially similar release at the Separation Date, and continued compliance

with (i) covenants prohibiting his engagement in competitive activities and solicitation of clients and employees, in each case for a

period of one year after the Separation Date and (ii) covenants prohibiting disclosure of the Company’s confidential information

and disparagement of the Company, subject to applicable law.

The foregoing description of the Separation Agreement

is a summary only and is qualified in its entirety by reference to the full text of the agreement, a copy of which is attached as Exhibit

10.1 to this Amendment and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

10.1

Separation Agreement and General Release, dated as of September 15, 2026, by and between the Company and Michael Weiner.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

GENPACT LIMITED

Date: September 18, 2026

By:

/s/ Sydney Schaub

Name:

Sydney Schaub

Title:

Senior Vice President, Chief Legal Officer and Secretary

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2625719d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

PLEASE

READ CAREFULLY AND

CONSULT

WITH AN ATTORNEY BEFORE SIGNING

THIS

SEPARATION AGREEMENT AND GENERAL RELEASE INCLUDES A

RELEASE

OF ANY AND ALL KNOWN AND UNKNOWN CLAIMS AGAINST GENPACT

YOU DO NOT UNDERSTAND THE DOCUMENT FULLY, DO NOT SIGN IT

SEPARATION

AGREEMENT AND GENERAL RELEASE

This

SEPARATION AGREEMENT and GENERAL RELEASE (the “Agreement”) is made this 15th day of September 2026, by and

between Michael Weiner, along with anyone who has or obtains any legal rights or claims through him (collectively, “Employee”),

and Genpact Limited and its related and/or affiliated companies (“Genpact” or the “Company”).

WHEREAS, Employee has

been employed by Genpact since on or about August 2, 2021;

WHEREAS,

on August 2, 2021, Employee signed an Employment Agreement with Genpact (“Employment Agreement”), amended January 1, 2025;

WHEREAS,

Employee and Genpact have discussed Employee’s separation from Genpact; and

WHEREAS,

Employee and Genpact wish to resolve and fully and finally settle, compromise, and forever discharge any and all claims and issues

that have been raised, or which could have been raised, or which Employee has now or may ever have had against Genpact.

NOW, THEREFORE, IT IS STIPULATED

AND AGREED AS FOLLOWS:

1.             Termination of Employment. Employee agrees that his employment with Genpact will end effective March 31, 2027. (the “Date

of Termination”). Employee will cease working in his role as Genpact Chief Financial Officer on September 8, 2026. Beginning on

September 9, 2026 (the “Transition Date”), Employee agrees that he will cooperate fully with Genpact’s efforts to transfer

Employee’s duties and responsibilities to others as may be necessary to effectuate an orderly and effective transition. Employee

will remain as a full-time employee for the period from the Transition Date through the Date of Termination (the “Employment Term”).

Provided this Agreement has become effective and irrevocable and subject to its terms:

During the Employment Term, the Company will continue to pay Employee’s bi-weekly salary of Twenty Six Thousand Two Hundred Eighty

Eight Dollars and Forty Six Cents ($26,288.46), less applicable deductions and withholdings, to be paid on the regularly scheduled pay

dates, and in a regular manner consistent with Genpact’s normal payroll practices during the Employment Term. Any monies earned

during the Employment Term paid after the Date of Termination will be paid pursuant to the terms of this Paragraph 1(a) on a prorated

basis for that pay period pursuant to applicable law;

During the Employment Term, Employee will accrue the same employee benefits that Employee was receiving prior to the commencement of

the Employment Term, pursuant to the terms and conditions of the applicable controlling benefit plan documents;

During the Employment Term, Employee will assist on special projects as designated by Genpact, if needed, in addition to cooperating

in good faith with the Company in its efforts to transfer Employee’s duties;

The Company may terminate Employee’s employment for Cause (as that term is defined in the Employment Agreement), as determined

in the Company’s sole discretion, at any time during the Employment Term. If Employee is terminated for Cause or resigns during

the Employment Term, Employee shall only be entitled to receive those payments set forth in Paragraph 5(b) of the Employment Agreement,

subject to Employee signing this Agreement, and the Release of Claims attached as Exhibit A to this Agreement becoming irrevocable;

Should Employee’s employment end prior to March 31, 2027 for any reason, the date of Employee’s actual termination shall

be the Date of Termination. Subject to all conditions herein, including Employee’s execution and non-revocation of this Agreement

and the Release of Claims attached hereto as Exhibit A, if Employee’s employment ceases in accordance with Paragraph 5(c) of the

Employment Agreement, Employee shall be entitled to receive the benefits set forth in Paragraph 5(c);

Effective on the Date of Termination, Employee and/or his dependents (who are qualified beneficiaries) may be eligible to continue such

coverage at his (or their) own expense for the duration of the period for which he is (or they are) eligible pursuant to the provisions

of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). All coverage provided to Employee and/or

his dependents pursuant to this Paragraph shall be subject to the provisions of the applicable insurance policies and the continuation

provisions of COBRA (and any changes or amendments with respect to such plans, policies or statute); and

For the avoidance of doubt, the terms and conditions of Section 4(c) of the Employment Agreement remain in effect after the Termination

Date.

Return

of Company Property. Employee agrees to return all Company property in Employee’s possession or control to Genpact

including, but not limited to, any computer equipment, office keys, credit and telephone cards, ID and access cards, and any and all

original and duplicate copies of checklists, cheat sheets, training material, , reports, company files, calendars, books, employee

handbooks, records, notes, notebooks, correspondence, customer lists, manuals, computer programs, computer disks, diskettes and any

other magnetic and other media materials containing confidential or proprietary information concerning Genpact no later than ten

(10) days after the Date of Termination.

3.           Consideration. Employee

acknowledges that the Company is providing material value to him by allowing him to remain employed during the Employment Term,

without requiring him to perform his former regular job duties or to report to the Company’s offices or facilities, in that

(i) Employee will continue to receive his full salary without performing such day-to-day job duties as were required prior to the

execution of this Agreement, and (ii) by remaining as an Employee through March 31, 2027, Employee will have the opportunity to vest

in and receive those equity awards described in Paragraph 3(c)(2) and (c)(3) below, to which he otherwise would have no entitlement.

In order to provide this consideration, and to fulfill all other obligations to Employee, and in consideration for Employee signing

this Agreement, the Release of Claims attached as Exhibit A to this Agreement becoming irrevocable, Employee’s submission of

all actuals and receipts for any outstanding Company expenses (if any as of the Date of Termination), Employee’s return of all

Company property referred to in paragraph 2, and in full satisfaction of all of the Company’s obligations to Employee, the

Company agrees that:

Payments Pursuant to Section 5(b) of the Employment Agreement. On the Date of Termination, or as soon as practicable following

such Date of Termination and in accordance with applicable law, Company will pay Employee, in a lump sum, any accrued but unpaid Base

Salary, any earned but unpaid Annual Bonus for the Fiscal Year preceding the Fiscal Year in which the Date of Termination occurs, and

any benefits accrued and due under any appliable benefit plans or programs of the Company. Such payments shall be made regardless of

whether Employee executes the Release of Claims attached hereto as Exhibit A and are not offered or made in consideration for the releases

or waivers contained therein.

Payments Pursuant to Section 5(c) of the Employment Agreement. If Employee remains employed through March 31, 2027, and

this Agreement and the Release of Claims attached hereto as Exhibit A have both been executed and have both become irrevocable, then

Company will also provide Employee with the following, in accordance with and subject to the conditions stated in Section 5(c) of the

Employment Agreement:

(i) A severance

payment in an amount equal to Six Hundred Eighty-Three Thousand Five Hundred Dollars ($683,500) equaling twelve (12) months of

Employee’s Base Salary at the rate then in effect as of the Date of Termination (the “Severance Amount”). The

Severance Amount shall be paid in equal installments, less applicable deductions, over the twelve-month period following the Date of

Termination, in accordance with the Company’s payroll practices. Payment of the Severance Amount will commence within sixty

days following the Date of Termination, and any installments due but not paid between the Date of Termination and the date of the

first payment will be paid with the first payment.

(ii) A lump sum

payment of Forty Five Thousand Three Hundred Twenty Seven Dollars) ($45,327), less applicable deductions, representing the cost that

would be payable by the Company, as measured as of the Termination Date, to obtain continued health care coverage for Employee and

Employee’s spouse and eligible dependents, as applicable, under the Company’s employee group health plan for the

eighteen-month period following the Date of Termination, at the level in effect for each of them on the Date of Termination. Payment

of this amount will be made within sixty days following the Date of Termination.

(iii) A lump sum

payment of One Hundred Sixty-Eight Thousand Five Hundred Thirty Four Dollars ($168,534), less usual deductions, based on a proration

of Employee’s unpaid annual bonus for the fiscal year in which the Date of Termination occurs. Such payment shall be

calculated using the method described in Paragraph 5(c)(iii) of the Employment Agreement. Payment of this amount will be made within

sixty days following the Date of Termination.

Equity Awards Pursuant to Section 5(c) of the Employment Agreement. If Employee remains employed through March 31, 2027,

and this Agreement and the Release of Claims attached hereto as Exhibit A have both been executed and have both become irrevocable, then

Employee will be eligible to receive Equity Awards as follows:

(i) Subject to

Section 5(c)(iv)(a), Employee’s option with respect to any shares that have vested prior to the Date of Termination shall

terminate on the date that is six months following the Date of Termination or (if earlier) upon the expiration of the term of the

option.

(ii) Subject to

Section 5(c)(iv)(b) of the Employment Agreement, Sixteen Thousand Six Hundred Sixty Two (16,662) restricted share unit awards shall,

on the Date of Termination, become vested and payable with respect to the number of units (if any) that would have vested had

Employee continued in employment or service for a period of twelve months following the Date of Termination. The shares underlying

any restricted share units that vest under this Paragraph shall be issued on the Date of Termination or as soon as reasonably

practicable thereafter, but in no event later than the end of the calendar year in which the Date of Termination occurs.

(iii) Subject to

Section 5(c)(iv)(c) of the Employment Agreement, Employee’s outstanding performance share award granted on March 11, 2025 (the

“2025 PSU”) shall, as of March 10, 2028 (the end of the relevant Service Period, as such term is defined in the

Performance Share Award Agreement), become vested with respect to the number of shares (if any, as determined in accordance with the

agreement evidencing the award) that would have vested had Employee continued in employment or service for a period of twelve months

following the Date of Termination. The actual number of shares that vest under such performance share award following the Service

Period shall be based on the level of attainment of the performance objectives as determined in accordance with the relevant

Performance Share Award Agreement. Any shares that vest under this Paragraph shall be issued as soon as practicable following March

10, 2028, but in no event later than the fifteenth day of the third calendar month following the end of the Service Period on March

10, 2028. The Target Performance Shares (as such term is defined in the Performance Share Award Agreement)

subject to Employee’s 2025 PSU is Thirty Thousand Seven Hundred and Seven (30,707).

(iv) For the

avoidance of doubt, in the event that Employee violates the restrictive covenants set forth in Paragraph 14 below, Employee shall

not be entitled, after the date of such violations or activity (as the case may be), to receive any payouts, benefits or continued

vesting under this Paragraph 3 or its subparagraphs, and any unvested equity shall be immediately forfeited, and the Company may

take such other enforcement actions as set forth herein or permitted by applicable law.

Bonus. Except as provided in Paragraph 3(a) and (b)(iii) above, Employee will be ineligible to receive any bonus payment for

calendar years 2026 and 2027. Employee acknowledges that notwithstanding the foregoing, he already has received any bonus payment to

which he was entitled.

Fair Benefit. Employee understands and agrees that the consideration referenced in Paragraphs 3 and 4 above, and any other

benefit provided for in this Agreement, is more of a benefit than Genpact is required to provide to Employee under any policy, plan,

procedure or contract with Genpact. Employee acknowledges that he has not made any claims or allegations related to sexual harassment

or sexual abuse and that none of the payments set forth in this Agreement are related to sexual harassment or sexual abuse.

Non-Admission of Liability. This Agreement is not an admission of wrongdoing or liability of any kind by Genpact or any of

its former or current principals, officers, directors, representatives, agents, employees, and consultants, and any such wrongdoing and

liability is expressly denied. This Agreement is entered into by the parties to avoid and to end all controversies between them.

Continuing Obligations. Employee agrees that he will: (a) cooperate fully with Genpact in its efforts to transfer such duties

and responsibilities to others as may be necessary to effectuate an orderly and effective transition, including the retention of a suitable

successor; (b) respond to reasonable inquiries from Genpact’s representatives concerning Employee’s projects, activities

and matters under Employee’s supervision while he was a Genpact employee; and (c) respond to reasonable requests to cooperate with

Genpact and its representatives concerning any investigation, claim or lawsuit initiated by any person, organization or entity (including

any government agency) against Genpact and/or Employee including but not limited to assisting in the preparation of Genpact’s defense,

consulting with Genpact counsel, and attending, and/or if knowledgeable, testifying truthfully at any administrative arbitration, judicial

or other proceeding. In making requests pursuant to this Paragraph, Genpact agrees, where practicable, to consider the personal and business

commitments of Employee. The parties agree that Employee’s reasonable and good faith cooperation in performing such services is

a material term and condition of this Agreement.

Employee is required to participate in meetings, interviews, hearings or other proceedings, Genpact shall reimburse Employee at a rate

based on Employee’s salary as of the Date of Termination. Employee shall be paid in half-day increments.

General

Release. Employee forever waives, generally releases, and fully discharges Genpact, its parents, subsidiaries, affiliates,

divisions, joint ventures, and related entities, including but not limited to their predecessors, successors, and assigns, and their

past and present directors, officers, agents, employees, representatives, fiduciaries of any employee benefit plan or policy, in

both their individual and representative capacities and each of them (collectively, “Releasees”) of and from any and all

legally waivable claims, charges, demands, causes of action, fees, liabilities, and expenses (inclusive of attorneys’ fees) of

any kind whatsoever, whether known or unknown, suspected or unsuspected, by reason of any actual or alleged act, statement,

omission, transaction, practice or occurrence, or other matter up to and including the date of this Agreement, including but not

limited to:

all claims for any alleged unlawful denial of leave, discrimination, harassment, retaliation or reprisal, or other alleged unlawful

practices arising under any federal, state, or local statute, ordinance, or regulation, including without limitation, claims under

any of the following, and any equivalent statutes under applicable state or local law, including any amendments thereto, the

Occupational Safety and Health Act; the Environmental Protection Act; the Toxic Substances Control Act, the Family and Medical Leave

Act; Title VII of the Civil Rights Act of 1964; the National Labor Relations Act; the Workers Adjustment and Retraining Notification

Act; The Civil Rights Act of 1991, 42 U.S.C. Sections 1981,1983,1985, and 1988; the Age Discrimination in Employment Act (the

“ADEA”); the Older Workers Benefit Protection Act (the “OWBPA”); the Equal Pay Act; the Fair Credit

Reporting Act; the Americans with Disabilities Act; the Employee Retirement Income Security Act; the Civil Rights Acts; the Fair

Labor Standards Act; the Racketeer Influenced and Corrupt Organizations Act; the Sarbanes-Oxley Act, the Immigration Reform and

Control Act; the fair employment laws of the United States, Florida and New York, including but not limited to the Florida Civil

Rights Act of 1992, the Florida AIDS, AIDS-Related Complex, and HIV Discrimination Law, the Florida Equal Pay Law, the Florida Wage

Discrimination Law, the Florida Law Prohibiting Discrimination on the Basis of Sickle Cell Trait, the Florida Whistleblowers Law,

the Florida Minimum Wage Amendment, the Florida Minimum Wage Act, the New York Equal Pay Law, the New York Adoptive Parents' Child

Care Leave Law, the New York Labor Law, the New York Civil Rights Law, the New York State Human Rights Law, the New York City Human

Rights Law, the New York Whistleblowers Act, the New York Executive Laws, the New York General Obligations Law and all

amendments thereto, New York City Human Rights Law, the New York City Administrative Code §§ 8-101 et seq., the New York

City Administrative Code, including but not limited to Title 8, Chapter 1 and Title 20, Chapter 8, the Fair Chance Act, the New York

City Local Civil Rights Restoration Act, New York General Obligations Law, the Stop Sexual Harassment in New York City Act, the

Florida and New York State Labor Laws, the Florida and New York State wage and hour laws and all wage orders; the Florida and New

York State Employment Laws; the Florida and New York State Labor Laws; the United States, Florida, and New York State Constitutions

and the common law of Florida, New York and the United States;

all claims for alleged breach of contract (whether express, implied or oral); breach of the covenant of good faith and fair dealing;

promissory estoppel; breach of personnel policies or employee handbooks; torts, defamation; slander; infliction of emotional distress;

post traumatic stress disorder; negligence; fraud; misrepresentation; violation of public policy; claims for physical or emotional injury;

assault; battery; false imprisonment; invasion of privacy; interference with contractual or business relationships; and violation of

any other principle of common law;

all claims for compensation of any kind, including without limitation, wages, vacation pay, commissions, bonuses, Genpact’s Variable

Income Compensation Plan, expense reimbursements;

all claims related to any equity grants under any Genpact Limited, Genpact Corporation or any affiliated entity’s equity compensation

plan, including but not limited to restricted share units, performance share units and stock options; and

all claims for back pay, front pay, reinstatement, any equitable relief, compensatory damages, damages for alleged pain and suffering,

punitive damages, liquidated damages, and any claim for attorneys’ fees, costs, disbursements, and interest; provided however that

nothing in this Release shall release the Company from any of its obligations to Employee under the Employment Agreement (including,

without limitation, its obligation to pay the amounts and provide the benefits upon which this Release is conditioned) or any rights

Employee may have to indemnification under any charter or by-laws (or similar documents) of any member of the Company or any insurance

coverage under any directors and officers insurance or similar policies or any benefits vested and accrued as of the date hereof which

Employee has under any ERISA benefit plan.

Employee acknowledges that he is not releasing any claim arising after the date on which he signs this Agreement or any claim that is

not otherwise waivable under applicable law including, but not limited to, any breach of this Agreement.

The parties hereto

agree that this Agreement may be pleaded as a full defense to any action, suit or other proceeding covered by the terms hereof that is

or may be initiated, prosecuted or maintained by any such party or his, her or its heirs or assigns. Employee understands and confirms

that Employee is executing this Agreement voluntarily and knowingly, but that this Agreement does not affect Employee’s right to

claim otherwise under ADEA.

In furtherance

of, and solely to the extent provided by, the agreements set forth above, the parties hereby expressly waive and relinquish any and

all rights under any applicable statute, doctrine or principle of law restricting the right of any person to release claims that

such person does not know or suspect to exist at the time of executing a release, which claims, if known, may have materially

affected such person’s decision to give such a release. In connection with such waiver and relinquishment, the parties

acknowledge that they are aware that they may hereafter discover claims presently unknown or unsuspected, or facts in addition to or

different from those that they now know or believe to be true, with respect to the matters released herein. Nevertheless, it is the

intention of the parties to fully, finally and forever release all such matters, and all claims relating thereto, that now exist,

may exist or theretofore have existed, as specifically provided herein. The parties hereto acknowledge and agree that this waiver

shall be an essential and material term of the releases contained above. Nothing in this paragraph is intended to expand the scope

of the releases as specified herein.

10.

Work Related Injuries, Expenses, Wrongs and No Compensation Due. Employee agrees that he has not suffered any job or

work-related injuries such as any type of injuries for which Employee has not already submitted a claim for worker’s

compensation benefits. Further, Employee agrees that he has properly reported all hours he has worked, and that Employee has been

paid all wages, overtime, commissions or other compensation that the Company should have paid Employee through the Date of

Termination. Employee further agrees that he has not incurred any business-related expenses for which Employee has not already

sought reimbursement. Employee acknowledges that he is not entitled to any form of compensation or benefits from the Releasees other

than specifically described in this Agreement.

11.

No Responsibility for Attorneys’ Fees. Employee further understands and agrees that Genpact is not liable or responsible

for Employee’s attorneys’ fees and costs, if any, in this matter. Employee understands and agrees that any and all attorneys’

fees or costs owed to Employee’s counsel will be paid by Employee alone, and Employee waives any right to collect attorneys’

fees, disbursements or costs from Genpact pursuant to any claim under federal, state or local law, order or regulation.

12. No

Other Claims, No Participation in Other Claims, No Outside Employment.

Employee represents that, by signing this Agreement, he has agreed to release and waive any claims that he could have brought against

the Company to the maximum extent waivable by law, except for any claims, charges or complaints filed with the Securities and Exchange

Commission (SEC), which Employee may file before or after the Date of Termination.

Except for any claims, charges or complaints filed with the SEC, which Employee may file before or after the Date of Termination,

Employee represents that Employee has not filed any claims or causes of action of any kind against the Releasees with any local,

state or federal agency, court or tribunal, nor does Employee have any knowledge or reason to believe that anyone else has filed

such a charge or complaint on Employee’s behalf. Subject to Paragraph 15, to the maximum extent permitted by law, Employee

promises never to: i) file, prosecute, join, opt-in or participate in a lawsuit (including a collective, class or representative

action) or other complaint or charge asserting any claim released in this Agreement; ii) knowingly bring or participate in any

action against any Releasee under any unfair competition law or private attorney general law of any jurisdiction, nor shall Employee

participate as a class representative, class member or aggrieved employee in any current or future class, collective, representative

or private attorney general actions against any Releasees relating to any claim released in this Agreement, including, without

limitation, any potential class, collective and/or representative action, whether currently pending or filed after the effective

date of this Agreement; or iii) seek any damages, remedies, or other relief for Employee personally (any right to which Employee

hereby waives and promises never to accept) with respect to any claim released in this Agreement, except with respect to any claims,

charges or complaints filed with the SEC before or after Employee’s Date of Termination. If Employee should file such a

charge or complaint, or if any agency shall ever assume jurisdiction against the Releasees on behalf of Employee, he will be bound

by Employee’s waiver and general release herein and Employee will not accept any benefit or remedy which may be awarded as a

result of such charge(s) or complaint(s) to the maximum extent permissible by law, except this does not limit Employee's right to

receive an award for information provided to the SEC staff or any other securities regulatory agency or authority.

As of the date of signing this Agreement, Employee is not aware of any violations of law by any of the Releasees. As part of this settlement,

to the maximum extent permissible by law, Employee specifically waives, releases and disclaims any interest in any claim release by this

Agreement purportedly asserted on Employee’s behalf in any current or future class, collective, private attorney general and/or

representative actions, except the foregoing shall not apply to any claim, charge or complaint filed with the SEC, which Employee may

file before or after the Date of Termination. Employee further agrees that Employee will opt-out of or not opt-in to (as the case may

require) any such current or future actions which have been or may be filed against any of the Releasees and, if Employee fails or refuses

to do so, this Agreement may be used as Employee’s binding agreement to effectuate that intended outcome, except the foregoing

shall not apply to any claim, charge or complaint filed with the SEC, which Employee may file before or after the Date of Termination.

Employee represents that as of the date of signing this Agreement, Employee has not made any claims or allegations related to sexual

harassment, sexual assault or sexual abuse against Genpact.

13.          Confidentiality.

a.           Subject

to Paragraph 16, including Employee’s right to file a claim, charge or complaint with the SEC before or after the Date of

Termination, Employee understands and agrees that the existence and terms of this Agreement are strictly confidential. Employee

agrees that he will not disclose the terms and conditions of this Agreement except to Employee’s immediate family (spouse or

significant other, children and parents), counselors, tax advisors and attorneys and only if such individuals agree to the

confidentiality provisions herein. Unless compelled to testify at a deposition, administrative proceeding, trial, or as required by

law, government rule or regulation, Employee shall refrain from issuing any article, memorandum, release, publicity or statement,

whether oral or written, concerning the terms or conditions of this Agreement to the public. Subject to the exceptions in Paragraph

16 and elsewhere in this Agreement, if contacted or subpoenaed by a third party or attorney wherein it is apparent that Employee may

be asked to disclose confidential information in violation of this provision, Employee shall, as soon as possible, but in no event

later than three (3) business days after receiving such notice, provide written notification to Richard D. Sutton, Vice President

and Legal Counsel, Human Resources, Genpact, 521 Fifth Avenue, 14th Floor, New York, NY 10175.

Employee agrees and acknowledges that during the course of his employment, Employee was exposed to confidential and proprietary

business information about the Releasee’s businesses, including, but not limited to, information about its customers, their

needs, and ongoing work being performed on behalf of the Releasees as well as potential business opportunities and Genpact’s

sales strategy and analysis in addition to confidential and proprietary business information about Genpact’s clients, trade

secrets, consultant contracts, customer lists, client financial information such as costs, revenues and billing, company

financial projections, sources of supply, employment information and production, pricing policies, operational methods, notes, other

confidential documents, manuals, security access, equipment, methods, processes, systems, techniques, inventions, machines, computer

programs, and any and all other tangible items whether or not so labeled, and other business affairs of the Releasees and their

clients learned by Employee at any time (“Confidential Information”). Subject to Paragraph 16, Employee agrees to keep

secret and not use, except for the purpose of the performance of his role for the Company, all Confidential Information that

Employee received during the course of his employment and agrees not to disclose Confidential Information of Genpact, its

subsidiaries, affiliates and related companies, and Genpact’s clients to anyone outside of Genpact.

c.            All

memoranda, notes, lists, records, documents whether or not labeled “Confidential” (and all copies thereof), made or

compiled by Employee or made available to Employee concerning Genpact, whether at home or at work shall be Genpact’s property

and shall be delivered to Genpact promptly upon the execution of this Agreement.

Employee’s confidentiality obligations under this Agreement are in addition to, and not in place of, any existing confidentiality

agreements previously entered into between Employee and the Company, or any common law duties of confidentiality that Employee otherwise

owes to the Company.

14. Restrictive

Covenants.

Noncompetition. In consideration of the payments by the Company to Employee pursuant to this Agreement, Employee hereby covenants

and agrees that, during the Employment Term and for the twelve-month period following the Date of Termination, Employee shall not, without

the prior written consent of the Company, be employed by, engaged by, or otherwise assist, either as an individual on his or her own

or as a partner, joint venturer, employee, agent, consultant, officer, trustee, director, owner, part-owner, shareholder, or in any other

capacity, directly or indirectly, any of the entities listed on the competitor list attached as Exhibit B hereto, or any successor or

affiliates of such entity. The foregoing restriction shall not include the passive ownership of securities in any entity listed on Exhibit

B and exercise of rights appurtenant thereto, so long as such securities represent no more than two percent of the voting power of all

securities of such enterprise. For the avoidance of doubt, the non-competition restrictive covenants set forth herein and in the Employment

Agreement supersede any non-competition restrictive covenants in any equity award agreements that Employee has executed with Genpact.

Nonsolicitation. In further consideration of the payments by the Company to Employee pursuant to this Agreement, Employee hereby

covenants and agrees that, during the Employment Term and for the twelve-month period following the Date of Termination, Employee shall

not either directly or indirectly on the Employee’s own behalf or in the service or on behalf of others (i) attempt to influence,

persuade or induce, or assist any other person in so influencing, persuading or inducing, any employee or independent contractor of the

Company to give up, or to not commence, employment or a business relationship with the Company, (ii) unless otherwise in contravention

of applicable law, directly, or indirectly through direction to any third party, hire or engage, or cause to be hired or engaged, any

person who is or was an employee or independent contractor of the Company, or (iii) attempt to influence,

persuade or induce, or assist any other person in so influencing, persuading or inducing, any agent, consultant, vendor, supplier or

customer of the Company with whom Employee has had contact within the last twenty-four months

of his relationship with the Company or about whom Employee has confidential information to give

up or not commence, a business relationship with the Company.

Nondisparagement. In further consideration of the payments by the Company pursuant to this Agreement, Employee hereby covenants

and agrees not to defame or disparage any member of the Company, or any of the Company’s products, services, finances, financial

condition, capabilities or other aspect of or any of their business, or any former or existing managers, directors, officers, employees,

agents, affiliates or successors of, or contracting parties with, any member of the Company in any medium to any person without limitation

in time. Nothing in this section inhibits the ability of Employee to disclose illegal acts in the workplace, including but not limited

to sexual harassment, or file any claim, charge or complaint with the SEC before or after the Date of Termination. The Company hereby

agrees that its board of directors, the members of the Company Group and the executives, managers and officers of the members of the

Company Group shall not defame or disparage Employee in any medium to any person without limitation in time. Notwithstanding this provision,

either party may confer in confidence with his, her or its legal representatives and make truthful statements as required by law.

d.            The

parties agree that the provisions of this paragraph are reasonable and necessary. Employee understands that the provisions of

Paragraphs 14(a) and 14(b) may limit Employee’s ability to earn a livelihood in a business similar to the Company’s

business but he nevertheless agrees and hereby acknowledges that (i) such provisions do not impose a greater restraint than is

necessary to protect the goodwill or other business interests of the Company, (ii) such provisions contain reasonable limitations as

to time and scope of activity to be restrained, (iii) such provisions are not harmful to the general public, (iv) such provisions

are not unduly burdensome to Employee, and (v) the consideration provided hereunder is sufficient to compensate Employee for the

restrictions contained in Paragraphs 14(a) and 14(b). In consideration of the foregoing and in light of Employee’s education,

skills and abilities, Employee agrees that Employee shall not assert that, and it should not be considered that, any provisions of

Paragraphs 14(a) and 14(b) otherwise are void, voidable or unenforceable or should be voided or held unenforceable. It is expressly

understood and agreed that although Employee and the Company consider the restrictions contained in Paragraphs 14(a) and 14(b) to be

reasonable, if a judicial determination is made by a court of competent jurisdiction that the time or territory or any other

restriction contained in this Agreement is an unenforceable restriction against Employee, the provisions of this Agreement shall not

be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court

may judicially determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any

restriction contained in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such

finding shall not affect the enforceability of any of the other restrictions contained herein.

15.          Employment Reference. Employee agrees that he will direct all reference inquiries regarding Employee’s employment at

Genpact to the Genpact Human Resources Manager. Genpact will respond to inquiries concerning Employee’s employment with Genpact

by providing only Employee’s: (a) dates of employment; (b) title; and (c) a confirmation of ending salary, if Employee has already

provided the inquiring third party with his ending salary.

16.          Protected

Rights.

Nothing in this Agreement prohibits or restricts Employee (or Employee's attorney) from filing a charge or complaint with the SEC, the

Financial Industry Regulatory Authority (FINRA), any other securities regulatory agency or self-regulatory authority, the Equal Employment

Opportunity Commission (EEOC), the National Labor Relations Board (NLRB), the Occupational Safety and Health Administration (OSHA), or

any other federal, state, or local governmental agency or commission (collectively, "Government Agencies"). Employee further

understands that this Agreement does not limit the Employee's ability to lawfully communicate with any Government Agencies or otherwise

participate in any lawful investigation or proceeding that may be conducted by any Government Agencies in connection with reporting a

possible securities law violation without notice to the Company. This Agreement does not limit the Employee's right to receive an award

for information provided to the SEC staff or any other securities regulatory agency or authority.

If Employee should file such a charge or complaint with the EEOC, Employee acknowledges that Employee will not seek any damages, remedies,

or other monetary award, benefit, or relief for Employee personally (any right to which Employee hereby waives and promises never to

accept).

Nothing in this Agreement in any way prohibits or is intended to restrict or impede the Employee from exercising protected rights, should

any exist for Employee, under the National Labor Relations Act which cannot be waived by agreement.

Nothing in this Agreement prevents employee from disclosing a sexual assault claim or sexual harassment claim arising after the parties

have entered into this Agreement.

17.          Additional

Remedies.

Any breach by Employee of the provisions of Paragraphs 12, 13, or 14 of this Agreement shall be considered a breach of a material term

and condition of this Agreement and Genpact shall have, without limitation, the following rights and remedies, severally enforceable,

in addition to any other rights and remedies available to Genpact under this Agreement or otherwise have the right to have the covenants

contained in Paragraphs 12, 13, or 14 specifically enforced by any court having equity jurisdiction, it being agreed that any such breach

or threatened breach will cause irreparable injury to Genpact and that money damages will not provide adequate remedy to Genpact.

b.            Any breach by Employee of the provisions of Paragraphs 14(a) or (b) of this Agreement shall be considered a breach of a material term

and condition of this Agreement and Genpact shall have, without limitation, the following rights and remedies, severally enforceable,

in addition to any other rights and remedies available to Genpact under this Agreement or otherwise:

i. The right

to require Employee to account for and pay over to Genpact all compensation, profits, monies,

accruals, increments or other benefits (collectively, “Benefits”)

derived or received by Employee as the result of any transactions constituting a breach of any of the covenants contained in Paragraphs

14(a) or (b).

ii. The

right to require Employee: i) to forfeit all Benefits received under this Agreement, including

but not limited to the Consideration; and ii) immediately return all monies received and

forgive all rights to future payments under this Agreement.

18.

Capacity to Waive Claims. Employee expressly represents that Employee is able to effect a knowing and voluntary waiver and

general release of all claims, as contained herein, and to enter into this Agreement and General Release.

19.

Execution of the Agreement. This Agreement shall be binding and inure to the benefit of the heirs, trustees, executors, administrators,

successors and assigns of the respective parties. This Agreement may be executed in any number of counterparts, each of which shall be

deemed an original, but all of which together shall constitute one instrument. A manually signed copy of this Agreement delivered by

facsimile, email, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original

signed copy of this Agreement.

20. Governing

Law and Interpretation.

Except as otherwise provided in Paragraph 20(b) below, this Agreement is made and entered into in the State of New York and shall in

all respects be interpreted, governed and enforced under the laws of the State of New York. In the event that either party moves to enforce

the terms of this Agreement or pursue a claim for the breach of this Agreement, the prevailing party shall be entitled to reasonable

attorneys’ fees and costs. Should any provision of this Agreement be declared illegal or unenforceable by any court of competent

jurisdiction and cannot be modified to be enforceable, excluding the general release language, such provision shall immediately become

null and void, leaving the remainder of this Agreement in full force and effect.

If Employee has previously executed a mandatory arbitration agreement with the Company (the "Arbitration Agreement"),

then: (i) any dispute, controversy, or claim arising out of, relating to, or concerning this Agreement, including its breach,

validity, interpretation, or enforceability, shall be resolved in accordance with the terms of the Arbitration Agreement; and

(ii) any claims not covered by or not released by this Agreement that would otherwise fall within the scope of the Arbitration

Agreement shall remain subject to the Arbitration Agreement. For the avoidance of doubt, the Arbitration Agreement shall control the

resolution of all disputes described in this subsection "b," and the governing law, attorneys' fees, and severability

provisions of subsection "a" shall apply to any such arbitration to the extent not inconsistent with the terms of the

Arbitration Agreement.

21.

Resolution of Disputes and Waiver of Jury Trial. Only if Employee has not previously executed a mandatory arbitration agreement

with the Company, then any controversy or claim concerning or arising out of this Agreement, or the breach thereof, shall be decided

by the U.S. District Court for the Southern District of New York, or the Supreme Court of New York, New York County and all such claims

shall be adjudicated by a judge sitting without a jury.

22.

Section Headings. The section headings contained in this Agreement are solely for the purpose of reference, and not a part

of the Agreement of the parties, and shall not in any way affect the interpretation of this Agreement.

23.          Sole

and Entire Agreement. There are no representations, warranties, understandings or agreements, other than those expressly set

forth in this Agreement, provided that the terms of any agreement(s) entered into between Employee and Genpact, which by their terms

survive termination of Employee’s employment with the Company and/or any of its affiliates shall so survive, including any

such agreements relating to indemnification, arbitration, the confidentiality of information, non-solicitation of clients and

employees, ownership of inventions and non-competition, and the vesting of any equity shares. This Agreement, along with the terms

of those agreements that survive termination of Employee’s employment, set forth the entire agreement between the parties and

fully supersedes any and all prior agreements or understandings which may have existed between the parties and may not be modified,

except by a writing signed by all parties

24.

Employee’s Representations. Employee acknowledges and represents that: (a) Employee has been advised that this release

includes, but is not limited to, all claims under the ADEA and OWBPA arising up to and including the date of execution of this general

release; (b) Employee has been advised by Genpact that the execution of this Agreement is a very important decision that should not be

made before discussing it with Employee’s attorney, advisors, and immediate family; (c) Employee has had the opportunity to review

this Agreement with an attorney of his choice; (d) Employee has been advised to consider fully this general release before executing

it; (e) Employee has been given up to twenty one (21) calendar days to review and consider this document; and (f) Employee has seven

(7) days after signing this Agreement to revoke it by informing the Company in writing as provided by Paragraph 28. Employee and Genpact

agree that any changes made to this Agreement after delivery to Employee, whether material or immaterial, do not restart the running

of the consideration period set forth in subsection (e) above.

25.

Voluntary Nature of the Agreement. Employee acknowledges that he has read this document in its entirety and represents that

the terms and conditions of this Agreement have been explained to Employee by Employee’s attorneys. Employee fully understands

each and every term and condition of this Agreement, and Employee expressly agrees that the signing of this document is done KNOWINGLY

AND VOLUNTARILY.

26.

Breach of Agreement. In the event Employee breaches any of the provisions of this Agreement, to the extent provided by law,

Employee shall return to Genpact all of the Consideration referred to in Paragraph 3, except Employee may retain One Thousand Dollars

($1,000). This paragraph shall not be considered a waiver of or a limitation on the remedies available to Genpact for breach of this

Agreement. The parties further agree that if either party unsuccessfully attempts to avoid or set aside the terms of this Agreement,

including but not limited to the general release, or if either party successfully moves in a legal forum to enforce the terms and conditions

of this Agreement against the other party, the losing party shall be liable for the costs and attorneys’ fees of the successful

party in enforcing the terms and conditions of this Agreement.

27. Compliance

with Section 409A and Section 457A of the Code.

This Agreement and the benefits provided hereunder are intended to comply with Section 409A of the Internal Revenue Code of 1986, as

amended (“Code”) and the Treasury Regulations and other guidance promulgated thereunder and Section 457A of the Code and

the Treasury Regulations and other guidance promulgated thereunder, and the provisions of this Agreement shall be interpreted and construed

to be consistent with this intent. Severance benefits under this Agreement are intended to be exempt from Section 409A of the Code under

the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation pay” exception,

to the maximum extent applicable.

Notwithstanding any provision to the contrary in this Agreement, no payments or benefits to which Employee becomes entitled under

this Agreement shall be made or paid to Employee prior to the expiration of the six-month period measured from the date of the

Employee’s “separation from service” with the Company (as such term is defined in Section 409A-1(h) of the 409A

Regulations), if Employee is deemed at the time of such separation from service a "specified employee" for purposes of

Code Section 409A and such delayed commencement is required in order to avoid a prohibited distribution under Code Section

409A(a)(2). Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments deferred pursuant to this

Section 11 ( c)(ii) shall be paid in a lump sum to Employee, and any remaining payments due under this Agreement shall be paid in

accordance with the normal payment dates specified for them herein.

c.            All payments to be made upon a termination of employment under this Agreement may only be made upon a "separation from

service" under Section 409A of the Code. For purposes of Section 409A of the Code, each payment hereunder shall be treated as a

separate payment, and the right to a series of installment payments under this Agreement shall be treated as a right to a series of

separate payments.

d.            All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of

Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement be for expenses incurred during the

period specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a fiscal

year not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other fiscal year, (iii) the reimbursement

of an eligible expense be made no later than the last day of the fiscal year following the year in which the expense is incurred, and

(iv) the right to reimbursement or in-kind benefits not be subject to liquidation or exchange for another benefit.

e.            If and to the extent required by Code Section 457 A, and subject to Code Section 409A, any compensation hereunder, as adjusted for any

earnings and losses attributable thereto, shall be paid to Employee no later than the last day of the twelfth month after the end of

the taxable year of the Company during which the right to the payment of such compensation is no longer subject to a "substantial

risk of forfeiture" within the meaning of Code Section 457 A.

28.          Effective

Date, Revocation of Agreement. THIS AGREEMENT SHALL NOT BECOME EFFECTIVE UNTIL EIGHT (8) DAYS AFTER THIS AGREEMENT IS SIGNED

BY EMPLOYEE DURING WHICH TIME EMPLOYEE MAY REVOKE THIS AGREEMENT BY GIVING WRITTEN NOTICE OF SUCH REVOCATION NO LATER THAN THE CLOSE

OF BUSINESS ON THE EIGHTH DAY TO:

Richard Sutton

Associate General Counsel,

Employment Law

Genpact

521 Fifth Avenue, 14th Floor

New York, NY 10175

ANY SUCH REVOCATION SHALL BE

DELIVERED BY OVERNIGHT MAIL.

Michael Weiner:

Genpact Limited:

/s/ Michael Weiner

By:

/s/ Sydney

Schaub

Date:

09/15/2026

Title:

Sydney Schaub, Chief Legal Officer

Date:

09/15/2026

EXHIBIT A

RELEASE OF CLAIMS

FOR

AND IN CONSIDERATION OF the payments, benefits, and other promises to be provided to Michael Weiner (“Employee”) in connection

with the termination of his employment, in accordance with the September 15, 2026, Separation Agreement and General Release (the “Agreement”),

Employee, forever waives, generally releases, and fully discharges Genpact, its parents, subsidiaries, affiliates, divisions, joint ventures,

and related entities, including but not limited to their predecessors, successors, and assigns, and their past and present directors,

officers, agents, employees, representatives, fiduciaries of any employee benefit plan or policy, in both their individual and representative

capacities and each of them (collectively, “Releasees”) of and from any and all legally waivable claims, charges, demands,

causes of action, fees, liabilities, and expenses (inclusive of attorneys’ fees) of any kind whatsoever, whether known or unknown,

suspected or unsuspected, by reason of any actual or alleged act, statement, omission, transaction, practice or occurrence, or other

matter up to and including the date of this Agreement, including but not limited to:

all claims for any alleged unlawful denial of leave, discrimination, harassment, retaliation or reprisal, or other alleged unlawful practices

arising under any federal, state, or local statute, ordinance, or regulation, including without limitation, claims under any of the following,

and any equivalent statutes under applicable state or local law, including any amendments thereto, the Occupational Safety and Health

Act; the Environmental Protection Act; the Toxic Substances Control Act, the Family and Medical Leave Act; Title VII of the Civil Rights

Act of 1964; the National Labor Relations Act; the Workers Adjustment and Retraining Notification Act; The Civil Rights Act of 1991,

42 U.S.C. Sections 1981,1983,1985, and 1988; the Age Discrimination in Employment Act (the “ADEA”); the Older Workers Benefit

Protection Act (the “OWBPA”); the Equal Pay Act; the Fair Credit Reporting Act; the Americans with Disabilities Act; the

Employee Retirement Income Security Act; the Civil Rights Acts; the Fair Labor Standards Act; the Racketeer Influenced and Corrupt Organizations

Act; the Sarbanes-Oxley Act, the Immigration Reform and Control Act; the fair employment laws of the United States, Florida and New York,

including but not limited to the New York Equal Pay Law, the New York Adoptive Parents' Child Care Leave Law, the New York Labor Law,

the New York Civil Rights Law, the New York State Human Rights Law, the New York City Human Rights Law, the New York Whistleblowers Act,

the New York Executive Laws, the New York General Obligations Law and all amendments thereto, New York City Human Rights Law, the New

York City Administrative Code §§ 8-101 et seq., the New York City Administrative Code, including but not limited to Title 8,

Chapter 1 and Title 20, Chapter 8, the Fair Chance Act, the New York City Local Civil Rights Restoration Act, New York General Obligations

Law, the Stop Sexual Harassment in New York City Act, the Florida Civil Rights Act of 1992, the Florida AIDS, AIDS-Related Complex, and

HIV Discrimination Law, the Florida Equal Pay Law, the Florida Wage Discrimination Law, the Florida Law Prohibiting Discrimination on

the Basis of Sickle Cell Trait, the Florida Whistleblowers Law, the Florida Minimum Wage Amendment, the Florida Minimum Wage Act, the

Florida and New York State Labor Laws, the Florida and New York State wage and hour laws and all wage orders; the Florida and New York

State Employment Laws; the Florida and New York State Labor Laws; the United States, Florida , and New York State Constitutions and the

common law of Florida , New York and the United States;

all claims for alleged breach of contract (whether express, implied or oral); breach of the covenant of good faith and fair dealing;

promissory estoppel; breach of personnel policies or employee handbooks; torts, defamation; slander; infliction of emotional

distress; post-traumatic stress disorder; negligence; fraud; misrepresentation; violation of public policy; claims for

physical or emotional injury; assault; battery; false imprisonment; invasion of privacy; interference with contractual or business

relationships; and violation of any other principle of common law;

A-1

all claims for compensation of any kind, including without limitation, wages, vacation pay, commissions, bonuses, Genpact’s Variable

Income Compensation Plan, expense reimbursements;

all claims

related to any equity grants under any Genpact Limited, Genpact Corporation or any affiliated entity’s equity compensation

plan, including but not limited to restricted share units, performance share units and stock options; and

all claims for back pay, front pay, reinstatement, any equitable relief, compensatory damages, damages for alleged pain and suffering,

punitive damages, liquidated damages, and any claim for attorneys’ fees, costs, disbursements, and interest.

However,

Employee acknowledges that he is not releasing any claim arising after the date on which he signs this Release of Claims or any claim

that is not otherwise waivable under applicable law. Employee agrees not to sue Releasees on any of the released claims or join as a

party with others who may sue Releasees on any such claims, except the foregoing shall not apply to any claim, charge or complaint filed

with the Securities and Exchange Commission (SEC), which Employee may file before or after the Date of Termination. To the maximum extent

permitted by law, Employee agrees that he will not seek, and waives any right, to accept any relief or award from any charge or action

against Releasees before any federal, state, or local administrative agency or federal, state, or local court whether filed by him or

on his behalf with respect to any claim or right covered by the Release of Claims, except this does not limit the Employee's right to

receive an award for information provided to the SEC staff or any other securities regulatory agency or authority. Except with respect

to any award Employee receives for information provided to the SEC staff or any other securities regulatory agency or authority, if Employee

breaches this paragraph, then (i) he will return all monies received as consideration for the Agreement and indemnify Releasees for all

expenses incurred in defending the action including but not limited to the Company’s attorneys’ fees and costs, and (ii)

Releasees will be relieved of their obligations under the Agreement.

This

Release of Claims does not (i) prohibit or restrict Employee from initiating communications directly with, responding to any inquiries

from, providing confidential to, reporting possible violations of law or regulation to, from filing a charge or participating in a proceeding

or investigation with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission,

the SEC, the Department of Labor, the National Labor Relations Board, the Department of Justice, Congress, and any agency Inspector General;

(i) prohibit or restrict Employee from disclosing a sexual assault claim or sexual harassment claim arising after he has signed this

Release of Claims; or (ii) require Employee to notify the Company of such communications or inquiry.

Employee

acknowledges that this Release of Claims is independent of, but does not supersede, the Release contained in Paragraph 9 of the Agreement.

Employee further acknowledges that, in signing this Release of Claims, he has not relied on any promises or representations, express

or implied, other than those that are set forth expressly in the Agreement and this Release of Claims.

Employee further acknowledges that:

1. He

first received this Release of Claims on the date that he received the Agreement to which

it is attached as Exhibit A;

2. He understands

that, in order for this Release of Claims to be effective, he may not sign it prior to the

Date of Termination, but that if he wishes to receive the consideration, he must sign and

return this Release of Claims no later than seven (7) days

after the Date of Termination and no earlier than the Date of Termination;

3. He

has carefully read and understand this Release of Claims;

4. He was given

twenty-one (21) days to consider his rights and obligations under the Agreement and this

Release of Claims and to consult with an attorney about both;

5. As

of the date of signing this Release of Claims, Employee has not made any claims or allegations

related to sexual harassment, sexual assault or sexual abuse against Genpact, and as of the

date of Employee signing this Agreement, he does not have any claims related to sexual harassment,

sexual assault or sexual abuse against Genpact;

6. He

understands that this Release of Claims is LEGALLY BINDING and that by signing it he gives

up certain rights;

7. He

has voluntarily chosen to enter into this Release of Claims and has not been forced or pressured

in any way to sign it;

8. He acknowledges

and agrees that the consideration is contingent on execution of this Release of Claims, and

EMPLOYEE KNOWINGLY AND VOLUNTARILY AGREES TO RELEASE the Company and the Releasees from any

and all claims described above, known or unknown, in exchange for the benefits he has obtained

by signing, and that these benefits are in addition to any benefit he would have otherwise

received if he did not sign this Release of Claims;

9. He

has seven (7) days after he signs this Release of Claims to revoke it by notifying the Company

in writing to the address listed in Paragraph 28 of the Agreement. The Release of Claims

will not become effective or enforceable until the seven (7) day revocation period has expired;

10. This Release

of Claims includes a WAIVER OF ALL RIGHTS AND CLAIMS THAT EMPLOYEE MAY HAVE under the ADEA

and OWBPA; and

11. This

Release of Claims does not waive any rights or claims that may arise after this Release of

Claims becomes effective, which is seven (7) days after he signs it, provided that he does

not exercise his right to revoke it.

Intending to be

legally bound, Employee has signed this Release of Claims as of the date written below.

EMPLOYEE

By:

Date:

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 03, 2026

Cover [Abstract]

Document Type

8-K/A

Amendment Flag

false

Document Period End Date

Sep. 03, 2026

Entity File Number

001-33626

Entity Registrant Name

GENPACT LIMITED

Entity Central Index Key

0001398659

Entity Tax Identification Number

98-0533350

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Canon’s Court

Entity Address, Address Line Two

22 Victoria Street

Entity Address, City or Town

Hamilton

Entity Address, Country

Entity Address, Postal Zip Code

HM 12

City Area Code

441

Local Phone Number

298-3300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common shares, par value $0.01 per share

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration